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ABSTRACT
There is still controversy regarding the role of circulating endothelial and progenitor cells (CECs/CEPs) in the pathogenesis of systemic
sclerosis (SSc). Using a sequential Boolean gating strategy based on a 4-color flow cytometric protocol, an increased number of
CD31pos/CD184pos(CXCR4)/CD34pos/CD45pos and CD31pos/CD117pos (c-kit-R) /CD34pos/ CD45pos hematopoietic circulating progenitor cells
(HCPCs) was detected in SSc patients compared with healthy subjects. In SSc, no circulating mature and progenitor endothelial cells were
observed, while an enhanced generation of erythroid progenitor cells was found to be correlated with the presence of CD117+ HCPCs.
The presence of freshly detected CXCR4posHCPC was correlated either to the in vitro cultured spindle-shaped endothelial like cells (SELC)
with an endo/myelomonocytic profile or to SDF-1 and VEGF serum level. These data are related to more fibrotic clinical features of the
disease, thus supporting a possible role of these cells in fibrosis.
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Introduction
Recent studies demonstrated the presence of circulating
EPCs and CEPs that have been shown to contribute to tissue
regeneration and therapeutic vasculogenesis.1-2 Circulating
endothelial cells (CECs) are another cell population present in
a wide variety of human inflammatory and pathological con-
ditions (cancer, infectious and cardiovascular disease) suggest-
ing a role for these cells as a biomarker of vascular disease.3-5
The recruitment of circulating progenitor cells for vascular
repair seems to be correlated to the expression of specific hom-
ing receptors, such as CXCR4 (CD184), and to the concentra-
tion of the stromal derived factor-1 (SDF-1)/CXCL12 (CXCR-
4/SDF-1 axis) as their specific ligand.6 Pro-angiogenetic factors
(vascular endothelial growth factor-VEGF, erythropoietin, etc.)
may also be involved in the mobilization process.7 Systemic
sclerosis (SSc) is an autoimmune disease of unknown etiology
characterized by excessive fibrosis and microvascular abnor-
malities.8 The presence of CECs and CEPs in this disease con-
tinues to be controversial. In fact, an enhanced generation of
CEPs has been demonstrated in SSc9 and high levels of CECs
were found to be linked to the severity of pulmonary hyper-
tension in its early stages.10 Conversely, it has been suggested
that a defective vasculogenesis related to the absence of
CEPs/EPCs can explain vascular disease in SSc and in rheuma-
toid arthritis.11,12 
Due to the fact that no standardized methods are used to
define and detect these cells, the results are sometimes con-
flicting, and a functional and phenotypic overlap between
hematopoietic and endothelial progenitor cells has often been
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a source of misunderstanding.13,14 Since the methodolog-
ical approach must be able to adequately redefine the
nature of circulating progenitor cells, in this study we
proposed a sequential gating multiparametric flow-cyto-
metric analysis and progenitor cell replating assays with
the aim of better characterizing and enumerating the cir-
culating hematopoietic (HCPC) and/or endothelial pro-
genitor cells in SSc. Serum levels of angiogenic
cytokines, in particular the SDF-1, were correlated to the
presence of either freshly detected or cultured circulat-
ing progenitor cells  together with the clinical features in
order to evaluate their possible role in SSc pathogenesis.
Design and Methods
Patients 
Forty patients with SSc fulfilling the criteria for classi-
fication proposed by Le Roy et al.15 and according to
Medsger and Steen8 were enrolled in this study (Table
1). Human peripheral blood (PB) samples were also
obtained from 10 healthy subjects (NS) as controls
(mean age 43±7, range 27-49; 3 males/7 females) after
obtaining informed consent. All patients were evaluated
for modified Rodnan skin score (mRSS) and lung high
resolution computed tomography (HRCT) scored as
reported by Warrick et al.16 This study was carried out
with the approval of the local ethics committee. 
Flow cytometric analysis of circulating progenitor 
cell subsets from PB
A 4-color cytometric analysis of whole fresh peripher-
al blood (PB) samples was performed on a FACSCalibur
equiped with the four-color option (Becton Dickinson,
CA, USA) as previously described.17 In particular, the
presence of the supposed endothelial and progenitor
cells was evaluated in the gate of both CD31+CD45– and
CD34+CD45– cells and on the basis of their further pos-
itivity for other endothelial markers such as CD133,
CD146, CD105. Platelets or non-specifically stained
events, present in the gate of CD31+CD45– and identi-
fied as CD61+CD45– cells, were excluded from the
analysis. Negative controls with isotype matched non-
relevant monoclonal antibodies (mouse IgG1, IgG2a,
IgM) were tested in all experiments. The presence of
hematopoietic circulating progenitor cells, was evaluat-
ed in the gate of both CD31+CD45+ and CD34+CD45+
cells and on the basis of their further positivity for
CD184, CD117, CD33, CD4,CD11c antigens. 
Cell culture and adherent clonogenic assay
The PB samples from SSc patients were collected for
circulating progenitor cell isolation and the cell culture
was performed in four different liquid media.18 The
detection of possible endothelial colonies, were moni-
tored as previously described.4,19,20 The same PBMNC
were also seeded into semisolid medium (Methocult
H4434, Stem Cell Technologies Inc., Vancouver,
Canada) specific for the hematopoietic long-term cul-
ture colony forming unit assay and the clonogenic out-
put of hematopoietic progenitors was evaluated by
scoring in vitro colonies at day 14.
Immunohistochemical analysis 
Adherent cell colonies from SSc patients were stud-
ied in situ performing: tartrate-resistant acid phos-
phatase (TRAP), non specific a-naphthyl acetate
esterase (NSE) and inhibited a-naphthyl acetate esterase
(all from Sigma Aldrich), as recommended by the
International Committee for Standardization in
Haematology (ICSH) manufacturer’s guidelines.21
Cytokines assay
The presence and the serum levels of angiogenic
cytokines (VEGF, HGF, bFGF, PDGF-BB) were analyzed
using a Searchlight human angiogenesis array 2-multi-
plex assay (Tema Ricerca, Bologna Italy). Stromal
derived factor -1 (SDF-1) serum levels were also meas-
ured using a single ELISA kit (R&D Systems Inc). Data
were calculated using a standard curve generated with
specific standards, according to manufacturer’s recom-
mendations. 
Statistical analysis
The number of freshly detected HCPCs and the num-
ber of in vitro adherent colonies was compared with the
different SSc subsets and clinical features using non-
parametric statistics (Wilcoxon test). Data were com-
puted with the SystatTM for WindowTM. Correlation
between the different hematopoietic and non-
hematopoietic colonies with clinical and laboratory
findings was evaluated using Pearson’s test.
Results and Discussion
There is still controversy regarding the role of circulat-
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Table 1. Summary of the clinical characteristic of SSc patients
(pts). Patients were untreated at the time of the study.
Age Disease Autoantibodies bILD cmRSS
duration (Anti-topoisomerasi (0-51)
(months) I I/ ACA/ 
nucleolar/othersa)
dSSC 48.3 yrs 38.6 6/0/3/3 6 18
(12 pts) (range (range
23-60) 5-60)
lSSC 63.8 yrs 98 1/20/3/4 5 7
(28 pts) (range (range 
37-74) 8-125)
Whole 56 yrs 68.3 7/20/6/7 11 12.5
group 
(40 pts)
Some patients were treated with low-doses of steroid until three days before the
study. SdSSC: patients affected by a diffuse form of SSc; lSSc: patients affected by a
limited form of SSc. aothers= anti-nuclear antibodies (ANA), with different pattern
and anti-extractable nuclear antigen antibodies (ENA); ACA= anti-centromere
autoantibodies; bILD= interstitial lung disease, cmRSS= modified Rodnan total
skin score (Clements P et al. J Rheumatol 1995; 22:1281-85). We considered a
Warrick total score of  ≥7 as the minimum level for HRCT (lung high resolution
computed tomography) abnormalities to be indicative of significant interstitial lung
disease. lSSc resulted older than dSSc and healthy subjects (43±7).
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ing endothelial and progenitor cells (CECs/CEPs) in the
pathogenesis of the systemic sclerosis (SSc). The results
are sometimes conflicting due to a phenotypic overlap
between hematopoietic and endothelial progenitor
cells13,14 and to the lack of a standardized analytical
methodological approach.
In this study, whole fresh PB samples were analyzed
by a sequential Boolean gating strategy based on a 4-
color cytometric protocol as previously described.17 The
immunophenotypic results showed the lack of in partic-
ular CD146+ and CD133+ endothelial, respectively,
mature and progenitor CD31+CD45– endothelial cells
either in patients or in normal controls (Figure 1 A).
However, in agreement with Strijbos et al.22 a small pop-
ulation of CD31+CD45– circulating cells expressing some
endothelial associated markers (SSc patients, whole
group: 0.5%±0.4 SD; 0.6%±0.3 SD in l-SSc vs. 0.4%±0.4
SD in d-SSc) was observed and excluded from the
analysis on the basis of their positivity for platelet asso-
ciated CD61 marker, high SSC scatter and negativity for
CD34 and CD133 thus indicating their non-endothelial
derivation (Figure 1 B). 
To further investigate the presence of endothelial
cells, the immunophenotypic results were combined to
different progenitor culture assays 4,19,20 that we routine-
ly use for the growth of CECs and CEPs in patients with
hematologic disorders.19 In this study, progenitor and
mature endothelial cells were not detected in any of the
samples examined. Furthermore, we did not observe in
vitro differentiation of circulating progenitor cells
towards the endothelial lineage in any patients even in
the presence of different angiogenic cytokines for
extended long-term cultures (Figure 1, Table of culture
assay). 
These data, supporting the notion that neither mature
or endothelial progenitor cells are detectable in the
blood of SSc, are in agreement with the hypothesis of a
possible defective vasculogenesis, as previously suggest-
ed by other authors.11 Nevertheless, at day 5-7 small
adherent clusters of (10-100 cells) elongated and sprout-
ing cells with a characteristic spindle-shaped endothe-
lial-like (SELC) morphology appeared in liquid culture
for long-term hematopoietic cells (Figure 1 F). SELC
grow in a granulo-monocytic manner. The cytochemical
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Figure 1. Whole fresh PB samples were analyzed by  a sequential gating strategy based on a 4-color cytometric protocol. (A) Circulating
progenitor cells are gated on   viable CD34+CD45– and CD31+CD45– cell subsets; no supposed endothelial cells were observed in the
gate of CD34+CD45– . (B) Platelets or non-specifically stained events, present in the gate of CD31+CD45– and identified as CD61+CD45–
cells, were excluded from the analysis. (C-D-E) The presence of the hematopoietic circulating progenitor cells was assessed in parallel
and analyzed in the gate of CD34+CD45+ for their positivity also for other stem cell hematopoietic and endothelial/monocytic markers
(CD184, CD117, CD133).  (F) An example of SELC colony, cultured in liquid long-term medium is shown. SELC colonies appeared as spin-
dle/elongated shaped cells, growing in a granulo-monocytic manner, positive for specific and non-specific α-naphthyl acetate esterase
(NSE) at day 7 (G). With increasing culture age, SELC tend to fuse by giving rise to a multinucleated giant cells that resulted positive for
the specific tartrate-resistance reactivity (TRAP) reaction (H), as expected for osteoclasts. (I) The presence of elongated endothelial-like
cells (SELC) are also visible in semisolid medium during short-term clonogenic assay for hematopoietic progenitors (white arrow). Small
BFU-E colonies are also visible (black arrows). In the table, the clonogenic output of PB mononuclear cells either in liquid (M199, M5100,
LB, EBM) or in semisolid medium (for the growth of colony forming units granulocytes, monocytes and erythroblasts: CFU-GM,CFU-
GEMM,BFU-E) is reported and expressed as average ± standard deviation of the number of colonies scored. 
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reaction for α-naphthyl acetate esterase (NSE) resulted
positive on SELC (Figure 1G), but its inhibition with
NaF abrogated this positivity, as normally expected for
monocytes, thus confirming the monocytic nature of
these cells.13,14 After 30 days of culture, SELCs tended to
fuse, giving rise to multinucleated giant cells that result-
ed positive for the tartrate-resistant acid phosphatase
(TRAP) reaction (Figure 1H), as expected for osteoclasts.
Although cultured in different liquid media, SELC did
not display either in vitro adherent expansion capacity or
endothelial differentiation potential. 
Short-term hematopoietic clonogenic assays revealed
a statistically significant increase of circulating erythroid
hematopoietic clonogenic potential (Figure 1 I), assessed
as a number of cultured (burst forming unit erythrob-
lasts) BFU-E/105 PBMNC in the whole SSc patients
group (Figure 1 I) (frequency: 35% of limited form, and
46% of the diffuse form) compared with NS (all p val-
ues <0.005). 
On the other hand, an increased number of circulating
hematopoietic progenitor cells (in particular CXCR4
and c-kit-CD117-CD45 positive subsets) co-expressing
endothelial and monocytic markers were observed in
PB of SSc patients. In particular, a significantly increased
level of the different cell subsets gated on CD34+CD45+
was seen in the PB of SSc compared with that of NS,
CD184+ (CXCR4+ HCPCs: 0.047±0.009% SD vs.
0.019±0.002% SD in NS, p<0.002); CD117+ (c-kit-
HCPCs, also called stem cell factor-R: 0.027±0.008% SD
vs. 0.015±0.0014% SD in NS, p<0.005), and CD133
(0.018±0.010% SD vs. 0.012±0.0014% SD in NS,
p>0.003) (Figure 1 C, D, E). Comparable values were
found in dSSc and lSSc clinical forms.
Interestingly, in our study, the CXCR4+ hematopoiet-
ic progenitor cells subset, implicated in the stem cell
homing and mobilization process, was found to be cor-
related to the presence of cultured SELC, spindle-shaped
endothelial-like cell (Pearson test: r=0.79, p<0.005) that
resulted positive for endothelial, and myelomonocytic
surface markers and that showed a selective optimal
outgrowth under hematopoietic culture conditions. 
As far as the presence of c-kit -CD117- HCPCs cell
subsets is concerned, in SSc patients and, especially in
the dSSc subgroups, we further showed that CD117-
HCPCs cell subset positively correlated with the num-
ber of PB-BFU-E (p<0.005) therefore suggesting a prefer-
ential in vitro erythroid commitment of this circulating
hematopoietic cell subset. These findings are in agree-
ment with evidence that CD31 and CD117 antigens
could also be expressed on hematopoietic progenitor
cells committed in particular to the erythroid pathway.23
High serum levels of angiogenic cytokines (VEGF,
PDGF, EGF, IGF) and an increased concentration of SDF-
1 chemokine, particularly evident in the dSSc subgroup,
were observed (Figure 2), dSSc form differed significant-
ly in the levels of SDF-1 (p<0.003) and to a lesser extent
of VEGF (p<0.005) and HGF cytokines (p<0.003) as
compared with normal subjects. This, together with an
assumed defective vasculogenesis as suggested for SSc,
led us to speculate that elevated levels of angiogenic
cytokines, could be responsible for promoting the circu-
lating hematopoietic cells erythroid commitment rather
than the endothelial one, since in dSSc of the disease the
number of BFU-E in PB positively correlated with the
levels of SDF-1 (p=0.002) and of circulating CD117-
CPCs cell subset (p<0.005). These results are in agree-
ment with the findings in literature supporting the view
that these two populations share the same progenitor
known as hemoangioblast.23 However, this finding may
also be correlated to a subclinical hypoxiemic status in
SSc patients due to pulmonary disease. But no correla-
tion was found between hemoglobin levels and BFU-E
count in SSc patients, or between SSc and controls.  
Clinical data showed that the number of freshly cir-
culating CXCR4+ HCPCs positively correlated with
mRSS (p=0.005), pulmonary involvement (p<0.005), and
the severity score used to evaluate the interstitial lung
disease (p<0.002). A positive correlation among
CXCR4+ HCPCs and two factors, implicated in the pro-
genitor cell recruitment such as SDF-1 (p=0.005) and
VEGF (p=0.003) were still observed, especially in the
diffuse form of SSc. 
All these data seem to suggest a possible role for circu-
lating hematopoietic progenitor cells in the fibrotic
process of SSc. In particular, high SDF-1/VEGF serum
levels could play a role in facilitating the organ homing
of CXCR4pos-HCPCs and their perivascular positioning
and retention. During the course of the disease, if a
mechanism for vascular repair is defective, recruited
hematopoietic CXCR-4pos cells that are exposed to angio-
genic stimulatory factors could enhance the proliferation
of the in situ resident endothelial cells or could respond to
the microenvironmental conditions, as alternatively
polarized monocytes or fibrocytes, that we identify as in
vitro SELC, capable of strong stimulation of the fibrotic
process. Our data therefore agree with other findings
observed in a murine model of bleomycin-induced pul-
monary fibrosis24 where spindle-shaped fibrocyte-like,
resembling our SELC, has been found to play a role in
the process of lung fibrosis. In conclusion, the presence
of SELC could represent a useful biomarker in fibrotic
disease as well as in other pathological conditions. 
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Figure 2. The serum levels of different angiogenic cytokines such
as VEGF, PDGF, HGF, bFGF and the chemokine SDF-1, evaluated on
the serum of SSc patients is reported. VEGF and HGF displayed
the highest serum levels either in normal samples or in SSc
patients. SSc patients, in particular d-SSc differed significantly in
the levels of SDF-1, and to a lesser extent in the levels of VEGF
and HGF cytokines compared with normal subjects.
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